PARP1 and colorectal carcinoma: We revealed that all SENS-CRC-SCs developed resistance to CHK1i, but SENSMED-CRC-SCs acquired resistance more rapidly than SENSHIGH-CRC-SCs (Fig. 6d; Supplementary Fig. S6e), presumably for their higher PARP1 levels.